Based: Santa Clara, CA
Investors: OrbiMed Advisors, New Leaf Venture Partners, 5AM Ventures, Delphi Ventures, Sprout Group and Mediphase Venture Partners
Scoop: Relypsa was founded by a group of ex-Ilypsa executives who got the rights to four preclinical programs they had been developing before Amgen bought the company for $420 million in 2009. Relypsa's lead compound is RLY5016, which the company's site describes as a "high capacity cation binder for the management of hyperkalemia in congestive heart failure (CHF) and chronic kidney disease (CKD) patients."
Relypsa's $70 million Series B provides the company with enough funding to see it through Phase III trials of RLY5016. Its total venture haul is more than $100 million.